ArticleJAMA network open2025
State and Sociodemographic Trends in US Cigarette Smoking With Future Projections.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The U.S. Federal Menthol Ban: a Critical Step Toward Health Equity for African Americans.Journal of racial and ethnic health disparities · 2026Article
- Why the mortality penalty of smoking is rising over time.PNAS nexus · 2026Article
- Non-tobacco nicotine dependence is associated with increased complications following clavicle open reduction internal fixation.Archives of orthopaedic and trauma surgery · 2026Article
- Development and implementation of a rapid surveillance system for tobacco product retail availability in six U.S. sites.Preventive medicine reports · 2026Article
- Comprehensive Smoke-Free Laws and Cardiovascular Disease Mortality in US Counties.JAMA network open · 2026Article
- Trends and inequities in peptic ulcer mortality across the United States, 1999-2023.BMC gastroenterology · 2026Article
- Heart failure and tobacco use disorder: mortality trends and disparities in the United States.Annals of medicine and surgery (2012) · 2026Review
- Tobacco advertising, cross-over effects, and US adolescent progression from never to current tobacco use.BMC public health · 2026Article
- Socioeconomic characteristics, tobacco use, and service utilization by county poverty status among Oklahoma tobacco helpline registrants: A crossTobacco prevention & cessation · 2026Article
- Coronary heart disease and chronic obstructive pulmonary disease prevalence and temporal trends among United States adults: a national population-based study.Frontiers in epidemiology · 2026Article
- Social norms and the decline in US cigarette smoking: evidence from 30 years of US representative surveys.BMJ public health · 2026Article
- Association of Smoking Behavior, Intensity, and Time Since Cessation with Epigenetic Aging Biomarkers: Results from NHANES 1999-2002.medRxiv : the preprint server for health sciences · 2025Article
- Lung Cancer Incidence in Counties at Low and High Risk of Radon Exposure: A Population-Based SEER Analysis (1975-2022).medRxiv : the preprint server for health sciences · 2025Article
- Unveiling the Relation between Cellular Aging, Epigenetics and Cancer.Aging and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: There are still significant population-level health consequences of cigarette smoking in US states. Objective: To estimate whether differential sociodemographic trends in smoking prevalence since 1992 will close the prevalence gap between states by 2035. Design, Setting, and Participants: This cross-sectional study included data from 18 repeated, state-representative US Tobacco Use Supplement to the Current Population Surveys (TUS-CPS) from 1992 to 2022. Data were analyzed between June and October 2024. Main Outcomes and Measures: Nonlinear time series trends in smoking prevalence in US states from 1992 to 2022 were projected through 2035 and compared with recommended targets. States were grouped into tertiles using their 1990s prevalence. Differential change in sociodemographic groups were compared across tertiles. Results: The 18 surveys comprised 1 770 442 respondents (997 569 female [56.3%]; 146 865 Hispanic [8.3%], 160 751 non-Hispanic Black [9.1%], and 1 373 454 non-Hispanic White [78.0%]). From 1992 to 2022, all state tertiles experienced significant declines in smoking prevalence, each decreasing by approximately 13 percentage points from 2001 to 2022. In 2022, prevalence was 7.4% (95% CI, 6.9% to 7.9%) in tertile 1 (lowest 1990s prevalence), 10.0% (95% CI, 9.2% to 10.8%) in tertile 2, and 12.7% (95% CI, 11.9% to 13.4%) in tertile 3. Projections to 2035 indicated the prevalence gap closing between tertiles, to 3.8% (95% CI, 2.6% to 5.1%) in tertile 1, to 5.1% (95% CI, 3.2% to 7.2%) in tertile 2, and to 6.6% (95% CI, 4.8% to 9.1%) in tertile 3. The only sociodemographic trend that reduced the gap occurred among individuals aged 18 to 24 year (tertile 3 change, -21.3% [95% CI, -24.5% to -18.2%] vs tertile 1 change, -16.4% [95% CI, -18.5% to -14.4%]; P = .005). Yet age was not a significant factor in projected changes, as the decline in the group aged 50 years and older was greater in tertile 1 than 3 (-4.7% [95% CI, -5.7% to -3.8%] vs -2.3% [95% CI, -3.5% to -1.2%]; P < .001). By 2035, only 4 states (California, Utah, Hawaii, and Colorado) were projected to be significantly under the recommended target of 5% prevalence. Conclusions and Relevance: The findings of these repeated cross-sectional surveys suggest that the difference in cigarette smoking prevalence between historically high vs low prevalence states will shrink by 2035, primarily from much faster declines among young adults in the traditionally highest prevalence states. Slower prevalence declines among older adults are likely to slow the decline in health consequences in these states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.